Loading
Cell Therapy / Gene Therapy · review/perspective
Regenerative Therapy · June 15, 2026
A consensus or society position rather than new primary data.
This narrative review summarizes therapeutic advances in ALS from 2020 to 2026 across iPSC-based drug discovery, cell therapy, and gene therapy. It highlights the FDA accelerated approval of tofersen in April 2023 as the first genetic ALS treatment and describes emerging trials of gene-silencing therapeutics and identification of STMN2 as a TDP-43-downstream target relevant to sporadic ALS.
review/perspective. Patients with amyotrophic lateral sclerosis (ALS), including genetic and sporadic forms.
FDA accelerated approval of tofersen (Qalsody) in April 2023 marked the first treatment targeting a genetic cause of ALS Sporadic ALS constitutes approximately 90% of all cases STMN2 identified as downstream target of TDP-43 dysfunction, with company-reported interim Phase 1/2 ANQUR trial (QRL-201) data suggesting target engagement
No original efficacy or safety data presented; review only
Clinicians should be aware of the expanding ALS therapeutic landscape, particularly the first approved genetic treatment (tofersen) and emerging gene-silencing and TDP-43-targeting approaches that may eventually address the majority sporadic ALS population. Cell therapy efficacy remains unproven in adequately powered trials.
Narrative review synthesizing therapeutic developments across multiple ALS modalities without original comparative efficacy data.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should be aware of the expanding ALS therapeutic landscape, particularly the first approved genetic treatment (tofersen) and emerging gene-silencing and TDP-43-targeting approaches that may eventually address the majority sporadic ALS population. Cell therapy efficacy remains unproven in adequately powered trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Three converging therapeutic paradigms-iPSC-based drug discovery, cell transplantation, and gene therapy-have substantially expanded the therapeutic pipeline for amyotrophic lateral sclerosis (ALS) between 2020 and 2026. The FDA's accelerated approval of tofersen (Qalsody) in April 2023 marked the first treatment targeting a genetic cause of ALS. iPSC-derived drug candidates, including ropinirole and bosutinib, have completed early-phase clinical trials led by Japanese institutions. Cell therapies targeting neuroinflammation through regulatory T cells are being actively explored as immunomodulatory strategies, although efficacy remains to be established in adequately powered trials. Next-generation gene-silencing approaches-including RNA interference (RNAi) therapeutics and AAV-delivered microRNA-entered first-in-human trials in 2024-2025. The identification of STMN2 as a downstream target of TDP-43 dysfunction has opened a potential TDP-43-downstream nucleic acid therapeutic avenue for sporadic ALS, which constitutes approximately 90% of all cases, with company-reported interim data suggesting target engagement in the ongoing Phase 1/2 ANQUR trial (QRL-201). This review synthesizes the latest evidence across all three therapeutic domains, with attention to the hierarchy of evidence, regulatory milestones, and the pioneering contributions of Japanese research groups.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.